AzTrials
AzTrials

SarcopeniaNCT04985877

Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota in Sarcopenia Elderly

A study testing Yakult 300 LIGHT Fermented Milk in people with Sarcopenia and Inflammation, run by Taipei Medical University at 3 sites in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sarcopenia, which refers to the progressive loss of skeletal muscle mass and strength, shares many characteristics with other disease states typically associated with risks of falling and fracture, including osteoporosis, frailty, and obesity. Read more about this study

Who is it for?
Ages 65 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Sarcopenia, Inflammation, Aging
What is being tested?
Yakult 300 LIGHT Fermented Milk
Could I receive a placebo?
No, everyone receives an active treatment
How many people
132 participants
Where
3 sitesTaiwan
Study dates
23 Mar 2021to 23 Feb 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Older adult

Who may be able to join

  • Age between 65 and 85 years
  • No use of hormonal replacement therapy (women)
  • No hospital admissions within the last 3 months
  • Sarcopenia criteria:
  • Muscle mass: measured by using InbodyS10 and standardized by height, shown by skeletal muscle index [SMI=appendicular muscle mass (kg)/height (m2)]. Low muscle mass was defined as:
  • Men: SMI <7.0 kg/m2
Show all 20Show fewer
  • Women: SMI <5.4 kg/m2 (2) Handgrip strength: measured by electronic hand grip dynamometer. Low handgrip strength was defined as:
  • Men: <28 kg
  • Women: <18 kg (3) Limb strength: measured by Time for 5 times for chair stand method. Low limb strength was defined as:
  • Time for 5 times for chair stand: ≧12s Sarcopenia was defined by (1), (2) or (3) Sarcopenia plus Lactobacillus casei strain Shirota (LcS)
  • Age between 65 and 85 years
  • No use of hormonal replacement therapy (women)
  • No hospital admissions within the last 3 months
  • Sarcopenia criteria:
  • Muscle mass: measured by using InbodyS10 and standardized by height, shown by skeletal muscle index [SMI=appendicular muscle mass (kg)/height (m2)]. Low muscle mass was defined as:
  • Men: SMI <7.0 kg/m2
  • Women: SMI <5.4 kg/m2 (2) Handgrip strength: measured by electronic hand grip dynamometer. Low handgrip strength was defined as:
  • Men: <28 kg
  • Women: <18 kg (3) Limb strength: measured by Time for 5 times for chair stand method. Low limb strength was defined as:
  • Time for 5 times for chair stand: ≧12s Sarcopenia was defined by (1), (2) or (3)

Who cannot join

  • Active cancer: currently receiving cancer treatment or have received cancer treatment within the last 3 months
  • Weight change ≥ 5% or weight change ≥ 5 kg within the past 3 months
  • BMI > 35 kg/m2
  • Disease requiring chronic use of prescription corticosteroids
  • History of ischemic or hemorrhage stroke
  • Unstable or uncontrollable hypertension (>180/110 mmHg)
Show all 13Show fewer
  • Doing hemodialysis or peritoneal dialysis within the last 3 months
  • Participation in a structured physical exercise training program within the past 2 year; previous use of creatinine supplementation; use of drugs that can affect bone metabolism (e.g., glucocorticoids, bisphosphonates, vitamin D or calcium).
  • Antibiotics were used in the past 3 months.
  • Products of probiotic were used in the past 2 weeks.
  • Living abroad for one month in the past 3 months
  • Hyperthyroidism without medication therapy
  • Allergic to milk

Trial locations and contacts

3 sites in 1 country.

Taiwan3 sites
  • Taipei Medical University Hospital

    Taipei, 110

  • Taipei Medical University

    Taipei, 110

  • Wanfang Hospital

    Taipei

Other trials in Taiwan

About this study

Official title: The Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota on Sarcopenia in Elderly Taiwanese: Interactions With the Nutrients Utilization, Diversity of Gut Microbiota, Microbiota-derived Metabolites and Muscle Loss

Sarcopenia, which refers to the progressive loss of skeletal muscle mass and strength, shares many characteristics with other disease states typically associated with risks of falling and fracture, including osteoporosis, frailty, and obesity. Sarcopenia often is linked to an increase in connective tissue, muscle steatosis, impaired muscle metabolism, an increase in inflammatory markers, an increased stiffness of myofibers, slower kinetics in establishing myosin-actin crossing bridges, increased oxidative stress, mitochondria dysfunction, hormonal imbalance, and decreased capillary flow. In addition to the Lactobacillus casei strain, Shirota is a well-known probiotic strain that has been approved and is generally recognized as safe by the United States Food and Drug Administration. L. casei strain Shirota (LCS) has been suggested to confer health benefits. Investigators found that LCS decelerated age-related muscle loss via ensuring mitochondrial function in Senescence-Accelerated Mouse Prone 8 (SAMP8) mice. Investigators also found that 3-Indolepropionic Acid (IPA) is a microbiota-derived metabolite from a healthy intestinal gut. IPA is also a protective factor for the progression of chronic kidney disease in the Chinese population. This clinical trial focuses on the effect of fermented milk containing LCS on sarcopenia in elderly Taiwanese individuals. Investigators focus on the topic of the interaction of LCS with the diversity of the gut microbiota, microbiota-derived metabolites, and protein utilization. The proposal will have four research goals. First, investigators try to investigate whether long term supplementation LCS could restructure the gut microbiota composition and gut microbial metabolites to against Aging related -Gut Dysbiosis in elderly. Second, investigators also try to link the LCS play an important role on muscle loss and alternation of gut microbiota composition. Third, investigators try to study the LCS effect of muscle deterioration with aging, and highlight the two underpinning mechanisms (ROS and protein utilization) regulating declines in muscle mass and function. Fourth, Since IPA is important Microbiota-derived metabolites in health gut, investigators try to investigate whether LCS could play an important role on modulation of IPA production in GI. Fifth, investigators hope that investigators can through gut microbiota composition found some selective microbiota clusters perform positively correlation with IPA.

Read the detailed description
  1. Subject Enrollment The definition of sarcopenia is based on the algorithm of Asian Working Group for Sarcopenia (AWGS).
  2. Muscle mass: measured by using Inbody S10 and standardized by height, shown by skeletal muscle index [SMI=appendicular muscle mass (kg)/height (m2)]. Low muscle mass was defined as:
  • Men: SMI <7.0 kg/m2
  • Women: SMI <5.7 kg/m2
  1. Handgrip strength: measured by electronic hand grip dynamometer. Low handgrip strength was defined as:
  • Men: <28 kg
  • Women: <18 kg
  1. Limb strength: measured by Time for 5 times for chair stand method. Low limb strength was defined as:
  • Time for 5 times for chair stand: ≧12s Sarcopenia was defined by (1) and one of (2), or (3)
  1. Study intervention Test beverages, Yakult 300 LIGHT Fermented Milk containing LcS, were provided by Yakult Co., Ltd. (Taipei, Taiwan). The beverages were distributed and stored at temperatures ranging from 0-10°C. The LcS-fermented milk contained LcS at more than 3x10^10 CFU per 100-ml bottle.

The subjects would take 2 bottles per day (104 kcal/day). Study intervention should be taken twice daily at approximately the same time. All milks would be sent to participant weekly (14 bottles/week).

  1. Study assessment

3-1 Anthropometric measurement and Body Composition Assessment Anthropometric measurement data was detected height, weight, waist circumference, arm muscle circumference, hip circumference, and calf circumference using measure tape and weight scale.

Body composition was detected using bioelectrical impedance analysis (BIA) as a non-invasive test instrument.

3-2 BIA Subjects stand on met without shoes and socks. Arms do not touch the trunk part of body, and are spread naturally to a 15 degree angle away from trunk. The hand electrodes are marked THUMB for the thumb and MIDDLE for the middle finger. The foot electrodes should be positioned between examinee's anklebone and heel. Electric current was supplied from the electrodes on the tips of the heels of both feet and the fingertips of both hands.

3-3 Muscle strength Grip strength measured in standard conditions with a well-studied model of a handheld dynamometer with reference populations can be a reliable surrogate for more complicated measures of muscle strength in the lower arms or legs. The measurement uses electronic hand grip dynamometer. Low handgrip strength is defined in Men: <28 kg ; Women: <18kg. Limb strength measured by Time for 5 times for chair stand. Subjects sat and stood for five times, and calculated time by timer. Low limb strength is defined in time for Time for 5 times for chair stand: ≧12s.

3-4 Physical performance Physical performance was assessed by using 6-meter usual gait speed, TUG, and SPPB.

3-5 Gait speed Participants were instructed to walk from a standing start at a pace that was normal and comfortable for them or to walk as fast as participants could until participants reached the end of the marked path. A trained examiner walked behind the participant and stopped timing when the participant's foot contacted the floor at the end of the walking course. Participants were provided rest breaks as needed throughout the testing session. Low Physical performance is defined < 1 m/s.

3-6 TUG Participants were instructed to stand up from the chair, walk 3 meters forward and go back to sit on the chair. Low Physical performance is defined ≧ 20s.

3-7 SPPB Participants were followed to SPPB to do the test. Low Physical performance is defined ≦ 9 scores.

3-8 Gut Microbiota Composition and Microbiota-derived Metabolite Analysis

3-8-1 Fecal sample collection and Bacterial genomic DNA isolation Fresh fecal samples were collected from individual participant. Participants were instructed to place toilet paper at the front of the toilet bowl before defecation to prevent fecal contamination with urine or water. They were asked to defecate in the opposite direction of their usual practice, ensuring the feces were deposited onto the toilet paper. Using the collection stick provided in the sampling kit, participants collected fecal samples and transferred them into the provided tubes. One of the tubes contained a preservation solution, which required thorough mixing after sample collection. Both tubes were then stored in a freezer.

The genomic DNA was extracted by using the QIAamp DNA Stool Mini kit according to the manufacturer's protocol. DNA concentrations were measured by using NanoDrop2000. The fecal samples were stored at -80°C refrigerator.

3-8-2 16S rRNA amplicon and data analysis The V1-V9 region of the 16S rRNA gene by PCR were referred to the Illumina 16S Metagenomic Sequencing Library Preparation protocol. The amplicons were paired and sequenced on an Illumina Miseq 2000 platform according to manufacturer's protocol. The data was analyzed with Quantitative Insights into Microbial Ecology 2 (QIIME2). The UPARSE algorithm was used to align with identical sequences and determine the representative operational taxonomic unit (OTU) sequences. For sequences with 97% similarity, they were clustered as same OTU. Alpha diversity analysis (Shannon index) was performed using QIIME while beta diversity analysis was analyzed using weighted principal coordinate analysis (PCoA). The online Galaxy workflow framework was used to determine the linear discriminant analysis (LDA) effect size LEfSe).

3-8-3 Fecal Short Chain Fatty Acids (SCFAs), IPA and TMAO Determination The fecal samples were diluted in 0.5% phosphoric acid and homogenized. After centrifuge, the supernatant was mixed with 4-ethylpentanoic acid in ethyl acetate, and kept the supernatant at -20°C.

The untargeted metabolomics was performed using HPLC coupled with a Q-Exactive Orbitrap Plus mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) as previously described[42, 43]. Liquid chromatography was performed on HPLC system using a BEH C18 column (1.7 μM, 2.1 mm x 100 mm, Waters Corporation). The injection volume was 2 μL with a flow rate of 0.3 ml/min and the column temperature was maintained at 35°C. HPLC linear gradient conditions were: 0-0.5 min 1 % B, 0.5-2.5 min from 1 % B to 10 % B, 2.5-3.5 min 65 % B, 3.5-5.0 min from 35 % B to 100 % B, and 5.0-9 min 1 % B [solvent system A: water/formic acid (100:0.1, vol/vol); B: acetonitrile/formic acid (100:0.1, vol/vol)]. The capillary temperature and voltage (+ and -) were maintained at 275 °C and 3,600 and 3,200 V, respectively. The samples for quality control (QC) were prepared by mixing all the samples. Data were acquired by Thermo Data Analysis software Compound Discoverer TM2.0. The raw intensities were transformed and normalized. For multiple peaks mapped to the same metabolites, the average intensity value was used. The matrix was then subjected to principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) using the R ropls package (version 1.21.0) to obtain differential metabolites between groups.

3-9 Blood Analyses

3-9-1 Blood Sampling Blood samples were collected from the subjects at pre-test and post-test. Whole blood were placed in collection tubes containing K2EDTA and then stored at 4°C until analysis. For plasma preparation, blood samples were placed in collection tubes containing heparin and centrifuged at 3000 g for 10 minutes then took supernatant. For serum preparation, blood samples were placed in collection tubes and then centrifuged at 3000 g for 10 minutes then took supernatant. The plasma and serum were stored at -70°C until analysis.

All biochemical parameters were performed one day before the start of the intervention and at the end of intervention. Albumin, Prealbumin, Cholesterol, High HDL-C, LDL-C, Triglyceride, TSH, Free T4, hsCRP, HbA1c (%), fasting glucose, fasting insulin, HOMA-IR, ALT, AST, creatinine, eGFR, WBC, RBC, HGB, HCT, MCHC, platelet and RDW-CV were determined after fasting for 8 hrs.

3-9-2 Metabolic Parameters All of the metabolic measurements were performed one day prior to the start of the intervention and at the end of intervention. CBC, TSH, Free T4, Vit-D, Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, fasting glucose, fasting insulin, blood urea, nitrogen, plasma prealbumin, albumin, ALT, AST, HbA1c, HS-CRP, γ-GT, and creatinine were measured after fasting for 8 hrs.

3-9-3 Inflammatory Cytokines Analysis The inflammation-associated serum cytokines TNF-α, TGF-β, IL-6, IL-17, and IL-10 were analyzed using colorimetric kits (Elabscience, China). The procedures followed the kit instructions and were measured using an ELISA reader (Bio Tek, PowerWave XS2, City, State, USA).

3-9-4 Anti-oxidant marker analysis Many anti-oxidant enzymes in human bodies, like Superoxide dismutase (SOD) (Elabscience, China), Glutathione peroxidase (GPx) (biovision, City, State, USA), and Catalase (CAT) (biovision, City, State, USA). Enzymes in the serum were evaluated for the activity by ELISA kit. The procedures followed the kit instructions and were measured by the ELISA reader (Bio Tek, PowerWave XS2, City, State, USA).

3-9-5 Trace elements Approximately 1 mL of each whole blood sample was microwave digested with 3 mL of 65 % nitric acid (Ultrapure Reagent, J.T. Baker). Subsequently, investigators washed the residuals in microwave tubes with 2 % nitric acid and then filtered the digested fluids with 0.22 μm filter. The total filtered solutions were stored in 15 mL centrifuge tubes. The levels of Pb, Cd, As, Hg, Mn, Al, Tl, V, Na, K, Mg, Ca, Fe, Zn, Se were determined using inductively coupled plasma mass spectrometry (ICP-MS; Agilent 7800).

3-9-6 Immune function analysis Human peripheral bloods were separated from whole blood by using PluriMate (#44-91002-11). After separation, Fc receptors in PBMC were blocked by Fc blocker (Biolegend #422302), stained with monoclonal antibodies (CD3-EV450, CD4-AF488, CD8a-AF647, CD25- PE/Cyanine7, (Elabscience Biotechnology Inc.)), and analyzed by the Invitrogen™ Attune™ NxT acoustic focusing cytometer (Thermo Fisher Scientific).

3-10 Questionnaire

3-10-1 Basic information The researchers with IRB certificate helped subjects to fill their information they said in the basic personal information, including age, disease history, etc.

3-10-2 24-hour dietary recall 24-hour dietary recall is to recall past 24 hours food intake and records food items, cooking methods, portion sizes, and calorie calculation.

3-10-3 International physical activity questionnaire (iPAQ) iPAQ is used to estimate the types of intensity of physical activity and sitting time.

3-10-4 Food frequency questionnaire Food frequency questionnaire is used to estimate long-term dietary conditions.

3-10-5 Taiwan lifestyle assessment Lifestyle questionnaire is a thirteen-item questionnaire which is reported by patients themselves.

3-10-6 Patient Assessment of Constipation symptom (PAC-SYM) PAC-SYM is used to measure specific symptoms of patients with constipation, was developed in parallel with a complementary instrument to comprehensively measure disease QoL outcomes (PAC-QOL). These instruments can be used separately or together.

3-10-7 SARC-F questionnaire SARC-F is a five-item questionnaire, which is reported by patients themselves to screen for sarcopenia. The reflection is based on the patient's perception of his own strength, ability to walk, stand up from the chair, climb stairs and fall experience. More than 4 points may be at risk of sarcopenia.

3-10-8 Mini nutrition assessment (MNA) MNA is used to screen out high-risk groups of malnutrition. The maximum score obtained by MNA is 30 points, between 17-23.5 represents the risk of malnutrition, less than 17 points is malnutrition.

Being tested
Yakult 300 LIGHT Fermented Milk
Keywords
Sarcopenia, Inflammation, Aging, Lactobacillus casei strain Shirota
Medical subject headings
Sarcopenia, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Yakult 300 LIGHT Fermented MilkDietary supplement

    2 bottles of fermented Milk containing Lactobacillus casei Strain Shirota per day, Intervention for 12 weeks.

Study groups in NCT04985877
Study groupRoleWhat they receive
Sarcopenia plus LcS group(LcS)ExperimentalLcS group must conform to inclusion criteria of LcS group and exclusion criteria. NS group need to intervene Yakult light 300 supplementation. NS group need to finish pre test and post test.
Receives: Dietary Supplement: Yakult 300 LIGHT Fermented Milk
Sarcopenia group(SC)No interventionSC group must conform to inclusion criteria of SC group and exclusion criteria. NS group dosen't need to intervene Yakult light 300 supplementation. NS group need to finish pre test and post test.
non-sarcopenia group(NS)No interventionNS group must conform to inclusion criteria of NS group and exclusion criteria. NS group dosen't need to intervene Yakult light 300 supplementation. NS group only need to finish the post test.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Impact of LCS on the Change of Gut Microbiota

    The V1-V9 region of the 16S rRNA gene was amplified by PCR following the Illumina 16S Metagenomic Sequencing Library Preparation protocol and sequenced on an Illumina MiSeq 2000 platform. Data analysis used QIIME2 with UPARSE for OTU clustering (97% similarity), Shannon index for alpha diversity, weighted PCoA for beta diversity, and LEfSe via Galaxy for differential analysis.

    In sarcopenia patients, Synergistaceae and Oscillibacter are elevated while Bifidobacterium is reduced. Post-intervention improvement (decreased Synergistaceae/Oscillibacter, increased Bifidobacterium) alleviates dysbiosis, lowers inflammation, and enhances gut-muscle axis function.

    This shift boosts SCFA production, muscle protein synthesis, grip strength, and mass while reducing pathogen-induced insulin resistance for metabolic recovery and symptom relief.

    Measured: 12 week

Secondary outcomes (6)
  1. Impact of LCS on the Change of Sarcopenia Markers (Handgrip)

    Handgrip: The measurement used electronic hand grip dynamometer. Low handgrip strength was defined as Men: <28 kg; Women: <18kg.

    Measured: 12 week

  2. Impact of LCS on the Change of Sarcopenia Markers (Walk Speed)

    Walk speed: The time required for participants to walk 6 meters along the line.

    Measured: 12 weeks

  3. Impact of LCS on the Change of Sarcopenia Markers (Chair Stand Test & TUG Test)

    Chair stand test (second): Participants sat and stood five times, and time was calculated using a timer. Low limb strength was defined time ≧12s. TUG:Participants were instructed to stand up from the chair, walk 3 meters forward and go back to sit on the chair. Low Physical performance was defined ≧ 20s.

    Measured: 12 week

  4. Impact of LCS on the Change of Sarcopenia Markers (SPPB Score)

    The Short Physical Performance Battery (SPPB) is a validated objective assessment tool developed by the National Institute on Aging to evaluate lower extremity function in older adults. It comprises three standardized components administered in sequence: a balance test (side-by-side, semi-tandem, and tandem stands), a 4-meter gait speed test, and a five-times chair stand test, each scored from 0-4 based on time or ability, yielding a total score of 0-12. Higher scores (10-12: minimal limitations; 4-6: moderate; 0-3: severe) indicate better physical performance and predict lower risks of mobility disability, falls, hospitalization, and mortality. The SPPB takes ~10 minutes, requires minimal equipment, and demonstrates excellent reliability for clinical and research use in geriatric populations, including sarcopenia studies.

    Low Physical performance was defined ≦ 9 scores

    Measured: 12 weeks

  5. Impact of LCS on the Change of Inflammatory Biomarker

    Serum pro-inflammatory cytokines (IL-6 and TNF-α) and anti-inflammatory cytokines (IL-10, IL-17 and TGF-β) were determined by using ELISA Kits (Elabscience Biotechnology Inc) via ELISA reader (BioTek, PowerWave XS2, City, State, USA).

    Measured: 12 week

  6. Impact of LCS on the Change of Anti-oxidant Biomarker

    Superoxide dismutase (SOD) (E-BC-K019, Elabscience Biotechnology Inc.), Glutathione peroxidase (GPx) (E-BC-K096, Elabscience Inc.) and Catalase (CAT) (E-BC-K031, Elabscience Biotechnology Inc.) are antioxidant enzymes in human. Enzymatic activity in serum was determined by using ELISA Kits via ELISA reader (BioTek, PowerWave XS2, City, State, USA).

    Measured: 12 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2021
  2. Study start23 Mar 2021
  3. Primary completion23 Feb 2023
  4. Study completion23 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
132 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04985877
Sponsor's protocol ID
N202010025
Status last verified
Jan 2026
First submitted
16 Jun 2021
Last updated
17 Feb 2026
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Yakult 300 LIGHT Fermented Milk in people with Sarcopenia and Inflammation, run by Taipei Medical University at 3 sites in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Feb 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Impact of LCS on the Change of Gut Microbiota (time frame: 12 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in